Search
Edetic acid
go.drugbank.com/drugs/DB00974ApprovedInvestigationalVet approvedA chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Teprotumumab
go.drugbank.com/drugs/DB06343ApprovedInvestigationalFollowing a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was approved by
Testosterone enanthate
go.drugbank.com/drugs/DB13944ApprovedInvestigationalThis slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule.
Sodium chlorite
go.drugbank.com/drugs/DB13210InvestigationalAcidified sodium chlorite was approved by the U.S. Food and Drug Administration as of 2004, as an anti-microbial agent which is non-toxic, but not as a drug [A174811, L5413].
Dotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawn[A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016.
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). … Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta.
Tamsulosin
go.drugbank.com/drugs/DB00706ApprovedInvestigational[A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238]
Lobeline
go.drugbank.com/drugs/DB05137InvestigationalAn alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent.
Clomipramine
go.drugbank.com/drugs/DB01242ApprovedInvestigationalVet approvedIn non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood.
Chlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.